Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

BioAtla (United States) | Researchclopedia

Back to institutions

BioAtla (United States)

San Diego, Californiacompany

44

Works

1,270

Citations

18

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

Top Researchers

Ken Chen Zhejiang Chinese Medical University

1,057 works99,604 citationsh-index: 102

Recent Research

523 Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC

Mihaela Druta,Seth M. Pollack,et al.

20250 citations

Phagocytosis and Immune Regulation

Cancer Research and Treatments

Glycosylation and Glycoproteins Research

Pancreatic and Hepatic Oncology Research

Cancer Cells and Metastasis

Immunotherapy and Immune Responses

HER2/EGFR in Cancer Research

Vaccine Coverage and Hesitancy

Peptidase Inhibition and Analysis

Kewei Chen Jiangnan University

1,000 works46,060 citationsh-index: 110

Son Pham Baylor College of Medicine

52 works29,590 citationsh-index: 20

William J. Boyle BioAtla (United States)

93 works29,536 citationsh-index: 37

Michael G. Baker University of Otago

548 works17,986 citationsh-index: 65

Jing Wang Naval Medical Research Command

628 works14,802 citationsh-index: 61

1581P Results from a phase I dose escalation study of BA3182, a dual-conditionally active biologic (CAB) EpCAM x CD3 bispecific T cell engager in patients with treatment refractory metastatic adenocarcinoma

O. Danciu,Jacob Thomas,et al.

20250 citations

36O First-in-human phase I study of a dual-conditionally active biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma

Jennifer B. Goldstein,James Thomas,et al.

20252 citations

486P Preliminary results from a first-in-human phase I study of a dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, BA3182, in pts with treatment refractory metastatic adenocarcinoma

A. Starodub,James Thomas,et al.

20250 citations

It's time to change how we vaccinate for measles

Benjamín L. Sievers,Eric L. Sievers

20250 citations

First report of ROR2 directed therapy with a conditionally active antibody drug conjugate in advanced melanoma.

J. W. Keeling,Elinor Barsh,et al.

20251 citations